The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

T cells develop functional defects during HIV-1 infection, partially due to the upregulation of inhibitory receptors such as programmed death-1 (PD-1) and CTLA-4. However, the role of lymphocyte activation gene-3 (LAG-3; CD223), also known as an inhibitory receptor, in HIV infection remains to be de...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of immunology (1950) Vol. 194; no. 8; pp. 3873 - 3882
Main Authors Tian, Xiaoling, Zhang, Anli, Qiu, Chao, Wang, Wei, Yang, Yu, Qiu, Chenli, Liu, Aiping, Zhu, Lingyan, Yuan, Songhua, Hu, Huiliang, Wang, Wanhai, Wei, Qiang, Zhang, Xiaoyan, Xu, Jianqing
Format Journal Article
LanguageEnglish
Published United States 15.04.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract T cells develop functional defects during HIV-1 infection, partially due to the upregulation of inhibitory receptors such as programmed death-1 (PD-1) and CTLA-4. However, the role of lymphocyte activation gene-3 (LAG-3; CD223), also known as an inhibitory receptor, in HIV infection remains to be determined. In this study, we revealed that LAG-3 on T cells delivers an inhibitory signal to downregulate T cell functionality, thereby playing an immunoregulatory role during persistent HIV-1 infection. We observed that HIV-1 infection results in a significant increase in LAG-3 expression in both the peripheral blood and the lymph nodes. The upregulation of LAG-3 is dramatically manifested on both CD4+ and CD8+ T cells and is correlated with disease progression. As expected, prolonged antiretroviral therapy reduces the expression of LAG-3 on both CD4+ and CD8+ T cells. The ex vivo blockade of LAG-3 significantly augments HIV-specific CD4+ and CD8+ T cell responses, whereas the overexpression of LAG-3 in T cells or the stimulation of LAG-3 on T cells leads to the reduction of T cell responses. Furthermore, most LAG-3 and PD-1 are expressed in different T cell subsets. Taken together, these data demonstrate that the LAG-3/MHC class II pathway plays an immunoregulatory role, thereby providing an important target for enhancing immune reconstitution in HIV-infected patients. Additionally, the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell–mediated immune responses.
AbstractList T cells develop functional defects during HIV-1 infection, partially due to the upregulation of inhibitory receptors such as programmed death-1 (PD-1) and CTLA-4. However, the role of lymphocyte activation gene-3 (LAG-3; CD223), also known as an inhibitory receptor, in HIV infection remains to be determined. In this study, we revealed that LAG-3 on T cells delivers an inhibitory signal to downregulate T cell functionality, thereby playing an immunoregulatory role during persistent HIV-1 infection. We observed that HIV-1 infection results in a significant increase in LAG-3 expression in both the peripheral blood and the lymph nodes. The upregulation of LAG-3 is dramatically manifested on both CD4+ and CD8+ T cells and is correlated with disease progression. As expected, prolonged antiretroviral therapy reduces the expression of LAG-3 on both CD4+ and CD8+ T cells. The ex vivo blockade of LAG-3 significantly augments HIV-specific CD4+ and CD8+ T cell responses, whereas the overexpression of LAG-3 in T cells or the stimulation of LAG-3 on T cells leads to the reduction of T cell responses. Furthermore, most LAG-3 and PD-1 are expressed in different T cell subsets. Taken together, these data demonstrate that the LAG-3/MHC class II pathway plays an immunoregulatory role, thereby providing an important target for enhancing immune reconstitution in HIV-infected patients. Additionally, the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell-mediated immune responses.
T cells develop functional defects during HIV-1 infection, partially due to the upregulation of inhibitory receptors such as programmed death-1 (PD-1) and CTLA-4. However, the role of lymphocyte activation gene-3 (LAG-3; CD223), also known as an inhibitory receptor, in HIV infection remains to be determined. In this study, we revealed that LAG-3 on T cells delivers an inhibitory signal to downregulate T cell functionality, thereby playing an immunoregulatory role during persistent HIV-1 infection. We observed that HIV-1 infection results in a significant increase in LAG-3 expression in both the peripheral blood and the lymph nodes. The upregulation of LAG-3 is dramatically manifested on both CD4(+) and CD8(+) T cells and is correlated with disease progression. As expected, prolonged antiretroviral therapy reduces the expression of LAG-3 on both CD4(+) and CD8(+) T cells. The ex vivo blockade of LAG-3 significantly augments HIV-specific CD4(+) and CD8(+) T cell responses, whereas the overexpression of LAG-3 in T cells or the stimulation of LAG-3 on T cells leads to the reduction of T cell responses. Furthermore, most LAG-3 and PD-1 are expressed in different T cell subsets. Taken together, these data demonstrate that the LAG-3/MHC class II pathway plays an immunoregulatory role, thereby providing an important target for enhancing immune reconstitution in HIV-infected patients. Additionally, the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell-mediated immune responses.T cells develop functional defects during HIV-1 infection, partially due to the upregulation of inhibitory receptors such as programmed death-1 (PD-1) and CTLA-4. However, the role of lymphocyte activation gene-3 (LAG-3; CD223), also known as an inhibitory receptor, in HIV infection remains to be determined. In this study, we revealed that LAG-3 on T cells delivers an inhibitory signal to downregulate T cell functionality, thereby playing an immunoregulatory role during persistent HIV-1 infection. We observed that HIV-1 infection results in a significant increase in LAG-3 expression in both the peripheral blood and the lymph nodes. The upregulation of LAG-3 is dramatically manifested on both CD4(+) and CD8(+) T cells and is correlated with disease progression. As expected, prolonged antiretroviral therapy reduces the expression of LAG-3 on both CD4(+) and CD8(+) T cells. The ex vivo blockade of LAG-3 significantly augments HIV-specific CD4(+) and CD8(+) T cell responses, whereas the overexpression of LAG-3 in T cells or the stimulation of LAG-3 on T cells leads to the reduction of T cell responses. Furthermore, most LAG-3 and PD-1 are expressed in different T cell subsets. Taken together, these data demonstrate that the LAG-3/MHC class II pathway plays an immunoregulatory role, thereby providing an important target for enhancing immune reconstitution in HIV-infected patients. Additionally, the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell-mediated immune responses.
Author Wang, Wei
Hu, Huiliang
Qiu, Chenli
Yuan, Songhua
Yang, Yu
Liu, Aiping
Zhu, Lingyan
Zhang, Anli
Qiu, Chao
Wei, Qiang
Wang, Wanhai
Tian, Xiaoling
Xu, Jianqing
Zhang, Xiaoyan
Author_xml – sequence: 1
  givenname: Xiaoling
  surname: Tian
  fullname: Tian, Xiaoling
– sequence: 2
  givenname: Anli
  surname: Zhang
  fullname: Zhang, Anli
– sequence: 3
  givenname: Chao
  surname: Qiu
  fullname: Qiu, Chao
– sequence: 4
  givenname: Wei
  surname: Wang
  fullname: Wang, Wei
– sequence: 5
  givenname: Yu
  surname: Yang
  fullname: Yang, Yu
– sequence: 6
  givenname: Chenli
  surname: Qiu
  fullname: Qiu, Chenli
– sequence: 7
  givenname: Aiping
  surname: Liu
  fullname: Liu, Aiping
– sequence: 8
  givenname: Lingyan
  surname: Zhu
  fullname: Zhu, Lingyan
– sequence: 9
  givenname: Songhua
  surname: Yuan
  fullname: Yuan, Songhua
– sequence: 10
  givenname: Huiliang
  surname: Hu
  fullname: Hu, Huiliang
– sequence: 11
  givenname: Wanhai
  surname: Wang
  fullname: Wang, Wanhai
– sequence: 12
  givenname: Qiang
  surname: Wei
  fullname: Wei, Qiang
– sequence: 13
  givenname: Xiaoyan
  surname: Zhang
  fullname: Zhang, Xiaoyan
– sequence: 14
  givenname: Jianqing
  surname: Xu
  fullname: Xu, Jianqing
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25780040$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1v2zAMhoWhw5p2u-806LiLW8rWh30s0q8AATZg6a6GLNONAlvyJBvb_sl-bpU0uQwYdiIpPS8J8r0gZ847JOQjgysOvLre2WGYne-vGIecKfmGLJgQkEkJ8owsAPI8S8_qnFzEuAMACTl_R85zoUoADgvyZ7NF-jQGfJ57PVnvqO_o-uYhK2jKN3SJfR_pLXbWYaSafpub0Y8n9qedtvR-dmZf6Z7e_drqOR6-tGvp0oeACU3KA3lrI-qI9GvwzwFj3HPW0cfV92zlOjQTtvsBu5TF9-Rtp_uIH47xkjzd322Wj9n6y8NqebPOTFHkU1Y1pTG8K6oWTas74MoowaUpUbSct0YBE0wLyZtKlaZJO3dVwUVeNI3gVY7FJfn82ncM_seMcaoHG03aWjv0c6xZCaViwErxf1QqljPOC5nQT0d0bgZs6zHYQYff9enwCZCvgAk-xoBdbex0OOoUtO1rBvXe4frkcH10OAnhL-Gp9z8lL_j5rBw
CitedBy_id crossref_primary_10_3389_fimmu_2023_1152951
crossref_primary_10_3389_fimmu_2018_00019
crossref_primary_10_1016_j_biopha_2023_115750
crossref_primary_10_1093_infdis_jiz485
crossref_primary_10_1172_JCI80566
crossref_primary_10_1080_2162402X_2020_1756116
crossref_primary_10_1155_2016_1841690
crossref_primary_10_1016_j_trsl_2022_07_008
crossref_primary_10_1038_s41598_025_90688_8
crossref_primary_10_1128_jvi_01785_21
crossref_primary_10_1158_2326_6066_CIR_18_0243
crossref_primary_10_2147_JHC_S291553
crossref_primary_10_1093_bfgp_elz039
crossref_primary_10_3390_cells11203330
crossref_primary_10_1111_imr_13388
crossref_primary_10_3389_fmicb_2021_684016
crossref_primary_10_1128_mbio_02265_24
crossref_primary_10_3390_v9100289
crossref_primary_10_1097_COH_0000000000000444
crossref_primary_10_12677_ACM_2022_126865
crossref_primary_10_18632_oncotarget_18251
crossref_primary_10_1038_nri_2017_112
crossref_primary_10_3390_ijms22168742
crossref_primary_10_1016_j_trsl_2017_07_002
crossref_primary_10_1080_2162402X_2022_2054758
crossref_primary_10_3389_fimmu_2019_02310
crossref_primary_10_2174_1570162X18999200819172009
crossref_primary_10_1016_j_jim_2024_113757
crossref_primary_10_3389_fimmu_2023_1270881
crossref_primary_10_1038_s42003_022_03537_z
crossref_primary_10_1016_j_jaut_2020_102504
crossref_primary_10_3389_fimmu_2023_1123342
crossref_primary_10_7554_eLife_83737
crossref_primary_10_1111_sji_13248
crossref_primary_10_1002_rmv_1981
crossref_primary_10_1371_journal_ppat_1010673
crossref_primary_10_1111_bjh_15078
crossref_primary_10_3389_fonc_2022_872438
crossref_primary_10_1002_cyto_a_22983
crossref_primary_10_12677_ACM_2015_52014
crossref_primary_10_1111_cas_12986
crossref_primary_10_1371_journal_ppat_1007429
crossref_primary_10_1038_s41564_023_01353_7
crossref_primary_10_1007_s13205_020_02406_y
crossref_primary_10_1186_s41231_019_0052_5
crossref_primary_10_1016_j_vaccine_2020_04_015
crossref_primary_10_3389_fimmu_2018_00940
crossref_primary_10_3389_fimmu_2020_615317
crossref_primary_10_3389_fimmu_2021_771279
crossref_primary_10_1016_j_intimp_2016_12_005
crossref_primary_10_1016_j_ebiom_2022_103840
crossref_primary_10_1371_journal_pone_0219322
crossref_primary_10_1371_journal_ppat_1007650
crossref_primary_10_3390_ijms25179378
crossref_primary_10_3390_cancers15102718
crossref_primary_10_1136_jitc_2020_001014
crossref_primary_10_1186_s12967_017_1130_y
crossref_primary_10_3389_fimmu_2020_02188
crossref_primary_10_1111_myc_13542
crossref_primary_10_1371_journal_pone_0206256
crossref_primary_10_1172_jci_insight_163101
crossref_primary_10_1038_srep38162
crossref_primary_10_1016_j_jbc_2021_101042
crossref_primary_10_3390_biomedicines10112809
crossref_primary_10_3390_jcm13051210
crossref_primary_10_3389_fonc_2022_957208
crossref_primary_10_17816_clinpract627504
crossref_primary_10_3390_v14030581
crossref_primary_10_1002_JLB_4MR1019_189R
crossref_primary_10_3389_fimmu_2021_795121
crossref_primary_10_1053_j_gastro_2023_06_037
crossref_primary_10_1136_jitc_2024_008799
crossref_primary_10_1002_cti2_1336
crossref_primary_10_1093_infdis_jiaa269
crossref_primary_10_2174_1874613601711010091
crossref_primary_10_1016_j_isci_2021_103588
crossref_primary_10_1371_journal_ppat_1005349
crossref_primary_10_1089_aid_2022_0062
crossref_primary_10_1177_11779322211067365
crossref_primary_10_1007_s11684_017_0592_x
crossref_primary_10_1093_cei_uxae066
crossref_primary_10_3390_v15010147
crossref_primary_10_3389_fmolb_2024_1403021
crossref_primary_10_1089_vim_2015_0066
crossref_primary_10_3390_cells10092227
crossref_primary_10_1038_s41598_023_36468_8
crossref_primary_10_3390_immuno4030013
crossref_primary_10_3389_fimmu_2018_01095
crossref_primary_10_1128_JVI_02048_16
crossref_primary_10_3389_fimmu_2019_00291
crossref_primary_10_1016_j_coviro_2019_03_004
crossref_primary_10_1016_j_jri_2023_103799
crossref_primary_10_1155_2021_6166492
crossref_primary_10_1093_infdis_jiaa191
crossref_primary_10_3390_vaccines8030419
crossref_primary_10_2174_1573394719666230306121408
crossref_primary_10_4049_jimmunol_2100367
crossref_primary_10_1038_ncomms9495
crossref_primary_10_3389_fimmu_2018_00746
crossref_primary_10_3389_fimmu_2020_01223
crossref_primary_10_3389_fimmu_2020_01350
crossref_primary_10_3389_fimmu_2024_1329775
crossref_primary_10_3389_fimmu_2015_00418
crossref_primary_10_1007_s10238_023_01188_w
crossref_primary_10_1371_journal_pone_0180413
crossref_primary_10_3389_fimmu_2024_1501613
crossref_primary_10_1016_j_intimp_2023_110207
crossref_primary_10_3389_fonc_2024_1514578
crossref_primary_10_3390_ijms19072000
crossref_primary_10_3390_v12091051
Cites_doi 10.1093/infdis/jir165
10.1016/0008-8749(89)90259-1
10.4049/jimmunol.161.8.4058
10.4049/jimmunol.1401249
10.1006/cimm.1994.1313
10.1182/blood-2006-04-015164
10.1002/eji.1830241246
10.1038/362355a0
10.4049/jimmunol.0903879
10.1016/j.bbrc.2011.01.062
10.1073/pnas.1009731107
10.1002/eji.200323382
10.1097/QAD.0b013e3282eee548
10.1007/s11904-010-0066-0
10.1038/ni.2180
10.1182/blood-2006-09-044826
10.1084/jem.171.5.1393
10.1038/nm1482
10.1016/j.cca.2012.11.025
10.1111/j.1365-2567.2005.02145.x
10.1016/S0959-8049(01)00184-8
10.1002/eji.1830240112
10.1038/nature05115
10.1038/42030
10.4049/jimmunol.169.10.5392
10.1084/jem.20100466
10.1038/334530a0
10.1073/pnas.98.1.253
10.1038/32588
10.1182/blood-2010-11-317297
10.4049/jimmunol.174.2.688
10.1371/journal.ppat.1002840
10.1093/infdis/164.6.1051
10.1182/blood-2003-01-0273
10.1126/science.2431484
10.1172/JCI31184
10.1182/blood.V91.2.585
10.1084/jem.176.2.327
10.1186/1742-4690-10-31
10.1038/ni1515
10.1158/0008-5472.CAN-11-1620
10.1073/pnas.0702257104
10.1073/pnas.211205098
10.4049/jimmunol.172.9.5450
10.4049/jimmunol.168.8.3874
10.4049/jimmunol.1100714
10.4049/jimmunol.0803771
10.1089/aid.2012.0195
10.1084/jem.20081398
ContentType Journal Article
Copyright Copyright © 2015 by The American Association of Immunologists, Inc.
Copyright_xml – notice: Copyright © 2015 by The American Association of Immunologists, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T5
H94
DOI 10.4049/jimmunol.1402176
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Immunology Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList AIDS and Cancer Research Abstracts
CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1550-6606
EndPage 3882
ExternalDocumentID 25780040
10_4049_jimmunol_1402176
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
0R~
18M
2WC
34G
39C
53G
5GY
5RE
5VS
5WD
79B
85S
AARDX
AAYXX
ABCQX
ABDFA
ABEJV
ABGNP
ABJNI
ABOCM
ABPPZ
ABXVV
ACGFO
ACGFS
ACIWK
ACNCT
ACPRK
ADBBV
ADIPN
ADNWM
AENEX
AETEA
AFHIN
AFOSN
AFRAH
AGORE
AHMMS
AHWXS
AIZAD
ALMA_UNASSIGNED_HOLDINGS
ARBBW
BAWUL
BCRHZ
BTFSW
CITATION
D0L
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
IH2
K-O
KQ8
L7B
OCZFY
OK1
OWPYF
P0W
P2P
PQQKQ
R.V
RHI
ROX
RZQ
SJN
TR2
TWZ
W8F
WH7
WOQ
X7M
XJT
XSW
XTH
YHG
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T5
H94
ID FETCH-LOGICAL-c332t-9b8cc4f39decdaf047c7546c8e5d44dc70151a564b978cb040f934523bb5492e3
ISSN 0022-1767
1550-6606
IngestDate Fri Jul 11 05:24:40 EDT 2025
Fri Jul 11 10:06:19 EDT 2025
Thu Apr 03 06:58:59 EDT 2025
Tue Jul 01 05:33:03 EDT 2025
Thu Apr 24 23:10:02 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License https://academic.oup.com/pages/standard-publication-reuse-rights
Copyright © 2015 by The American Association of Immunologists, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c332t-9b8cc4f39decdaf047c7546c8e5d44dc70151a564b978cb040f934523bb5492e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25780040
PQID 1671214436
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_1808710185
proquest_miscellaneous_1671214436
pubmed_primary_25780040
crossref_citationtrail_10_4049_jimmunol_1402176
crossref_primary_10_4049_jimmunol_1402176
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-04-15
2015-Apr-15
20150415
PublicationDateYYYYMMDD 2015-04-15
PublicationDate_xml – month: 04
  year: 2015
  text: 2015-04-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of immunology (1950)
PublicationTitleAlternate J Immunol
PublicationYear 2015
References Okazaki (2025030706084892100_r24) 2011; 208
Lane (2025030706084892100_r44) 2010; 18
Zhang (2025030706084892100_r35) 2007; 109
Ipp (2025030706084892100_r43) 2013; 416
Pena (2025030706084892100_r34) 2014; 30
Workman (2025030706084892100_r19) 2003; 33
Maçon-Lemaître (2025030706084892100_r37) 2005; 115
Larsson (2025030706084892100_r5) 2013; 10
Woo (2025030706084892100_r23) 2012; 72
Andreae (2025030706084892100_r39) 2003; 102
Fox (2025030706084892100_r32) 1991; 164
Mengozzi (2025030706084892100_r46) 2001; 98
Sauce (2025030706084892100_r50) 2007; 21
(2025030706084892100_r51) 2011
Day (2025030706084892100_r6) 2006; 443
Workman (2025030706084892100_r18) 2002; 169
Peretz (2025030706084892100_r11) 2012; 8
Hsueh (2025030706084892100_r2) 1994; 159
Workman (2025030706084892100_r36) 2005; 174
Demeure (2025030706084892100_r31) 2001; 37
Workman (2025030706084892100_r29) 2004; 172
Kaufmann (2025030706084892100_r15) 2007; 8
Andreae (2025030706084892100_r38) 2002; 168
Bettini (2025030706084892100_r22) 2011; 187
Lanzavecchia (2025030706084892100_r40) 1988; 334
Aldy (2025030706084892100_r12) 2011; 405
Zhang (2025030706084892100_r14) 2011; 203
Hannier (2025030706084892100_r21) 1998; 161
Joosten (2025030706084892100_r28) 2007; 104
Barnaba (2025030706084892100_r41) 1994; 24
Chun (2025030706084892100_r45) 2001; 98
Khaitan (2025030706084892100_r47) 2011; 8
Kaufmann (2025030706084892100_r8) 2009; 182
Yamamoto (2025030706084892100_r9) 2011; 117
Trimble (2025030706084892100_r4) 1998; 91
Gandhi (2025030706084892100_r27) 2006; 108
Triebel (2025030706084892100_r16) 1990; 171
Banchereau (2025030706084892100_r48) 1998; 392
Walker (2025030706084892100_r3) 1989; 119
Baixeras (2025030706084892100_r42) 1992; 176
Cella (2025030706084892100_r49) 1997; 388
Xu (2025030706084892100_r30) 2014; 193
Jin (2025030706084892100_r10) 2010; 107
Huard (2025030706084892100_r20) 1994; 24
Walker (2025030706084892100_r1) 1986; 234
Camisaschi (2025030706084892100_r26) 2010; 184
Pantaleo (2025030706084892100_r33) 1993; 362
Grosso (2025030706084892100_r17) 2007; 117
Trautmann (2025030706084892100_r7) 2006; 12
Jones (2025030706084892100_r13) 2008; 205
Butler (2025030706084892100_r25) 2012; 13
References_xml – volume: 203
  start-page: 1668
  year: 2011
  ident: 2025030706084892100_r14
  article-title: B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jir165
– volume-title: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
  year: 2011
  ident: 2025030706084892100_r51
– volume: 119
  start-page: 470
  year: 1989
  ident: 2025030706084892100_r3
  article-title: CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals
  publication-title: Cell. Immunol.
  doi: 10.1016/0008-8749(89)90259-1
– volume: 161
  start-page: 4058
  year: 1998
  ident: 2025030706084892100_r21
  article-title: CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.161.8.4058
– volume: 193
  start-page: 4125
  year: 2014
  ident: 2025030706084892100_r30
  article-title: IFN-stimulated gene LY6E in monocytes regulates the CD14/TLR4 pathway but inadequately restrains the hyperactivation of monocytes during chronic HIV-1 infection
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1401249
– volume: 159
  start-page: 271
  year: 1994
  ident: 2025030706084892100_r2
  article-title: Suppression of HIV replication by CD8+ cell clones derived from HIV-infected and uninfected individuals
  publication-title: Cell. Immunol.
  doi: 10.1006/cimm.1994.1313
– volume: 108
  start-page: 2280
  year: 2006
  ident: 2025030706084892100_r27
  article-title: Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients
  publication-title: Blood
  doi: 10.1182/blood-2006-04-015164
– volume: 24
  start-page: 3216
  year: 1994
  ident: 2025030706084892100_r20
  article-title: Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.1830241246
– volume: 362
  start-page: 355
  year: 1993
  ident: 2025030706084892100_r33
  article-title: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
  publication-title: Nature
  doi: 10.1038/362355a0
– volume: 184
  start-page: 6545
  year: 2010
  ident: 2025030706084892100_r26
  article-title: LAG-3 expression defines a subset of CD4+CD25highFoxp3+ regulatory T cells that are expanded at tumor sites
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0903879
– volume: 405
  start-page: 503
  year: 2011
  ident: 2025030706084892100_r12
  article-title: 2B4+ CD8+ T cells play an inhibitory role against constrained HIV epitopes
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2011.01.062
– volume: 107
  start-page: 14733
  year: 2010
  ident: 2025030706084892100_r10
  article-title: Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1009731107
– volume: 33
  start-page: 970
  year: 2003
  ident: 2025030706084892100_r19
  article-title: The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200323382
– volume: 21
  start-page: 2005
  year: 2007
  ident: 2025030706084892100_r50
  article-title: PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e3282eee548
– volume: 8
  start-page: 4
  year: 2011
  ident: 2025030706084892100_r47
  article-title: Revisiting immune exhaustion during HIV infection
  publication-title: Curr. HIV/AIDS Rep.
  doi: 10.1007/s11904-010-0066-0
– volume: 13
  start-page: 188
  year: 2012
  ident: 2025030706084892100_r25
  article-title: Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2180
– volume: 109
  start-page: 4671
  year: 2007
  ident: 2025030706084892100_r35
  article-title: PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors
  publication-title: Blood
  doi: 10.1182/blood-2006-09-044826
– volume: 171
  start-page: 1393
  year: 1990
  ident: 2025030706084892100_r16
  article-title: LAG-3, a novel lymphocyte activation gene closely related to CD4
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.171.5.1393
– volume: 12
  start-page: 1198
  year: 2006
  ident: 2025030706084892100_r7
  article-title: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
  publication-title: Nat. Med.
  doi: 10.1038/nm1482
– volume: 416
  start-page: 96
  year: 2013
  ident: 2025030706084892100_r43
  article-title: The paradox of the immune response in HIV infection: when inflammation becomes harmful
  publication-title: Clin. Chim. Acta
  doi: 10.1016/j.cca.2012.11.025
– volume: 115
  start-page: 170
  year: 2005
  ident: 2025030706084892100_r37
  article-title: The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2005.02145.x
– volume: 37
  start-page: 1709
  year: 2001
  ident: 2025030706084892100_r31
  article-title: T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts
  publication-title: Eur. J. Cancer
  doi: 10.1016/S0959-8049(01)00184-8
– volume: 24
  start-page: 71
  year: 1994
  ident: 2025030706084892100_r41
  article-title: Professional presentation of antigen by activated human T cells
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.1830240112
– volume: 443
  start-page: 350
  year: 2006
  ident: 2025030706084892100_r6
  article-title: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
  publication-title: Nature
  doi: 10.1038/nature05115
– volume: 388
  start-page: 782
  year: 1997
  ident: 2025030706084892100_r49
  article-title: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
  publication-title: Nature
  doi: 10.1038/42030
– volume: 169
  start-page: 5392
  year: 2002
  ident: 2025030706084892100_r18
  article-title: Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.169.10.5392
– volume: 208
  start-page: 395
  year: 2011
  ident: 2025030706084892100_r24
  article-title: PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20100466
– volume: 334
  start-page: 530
  year: 1988
  ident: 2025030706084892100_r40
  article-title: T cells can present antigens such as HIV gp120 targeted to their own surface molecules
  publication-title: Nature
  doi: 10.1038/334530a0
– volume: 98
  start-page: 253
  year: 2001
  ident: 2025030706084892100_r45
  article-title: Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.98.1.253
– volume: 392
  start-page: 245
  year: 1998
  ident: 2025030706084892100_r48
  article-title: Dendritic cells and the control of immunity
  publication-title: Nature
  doi: 10.1038/32588
– volume: 117
  start-page: 4805
  year: 2011
  ident: 2025030706084892100_r9
  article-title: Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection
  publication-title: Blood
  doi: 10.1182/blood-2010-11-317297
– volume: 174
  start-page: 688
  year: 2005
  ident: 2025030706084892100_r36
  article-title: Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.174.2.688
– volume: 18
  start-page: 2
  year: 2010
  ident: 2025030706084892100_r44
  article-title: Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation
  publication-title: Top. HIV Med.
– volume: 8
  start-page: e1002840
  year: 2012
  ident: 2025030706084892100_r11
  article-title: CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1002840
– volume: 164
  start-page: 1051
  year: 1991
  ident: 2025030706084892100_r32
  article-title: Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/164.6.1051
– volume: 102
  start-page: 2130
  year: 2003
  ident: 2025030706084892100_r39
  article-title: MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)
  publication-title: Blood
  doi: 10.1182/blood-2003-01-0273
– volume: 234
  start-page: 1563
  year: 1986
  ident: 2025030706084892100_r1
  article-title: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication
  publication-title: Science
  doi: 10.1126/science.2431484
– volume: 117
  start-page: 3383
  year: 2007
  ident: 2025030706084892100_r17
  article-title: LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI31184
– volume: 91
  start-page: 585
  year: 1998
  ident: 2025030706084892100_r4
  article-title: Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3ζ, the signaling chain of the T-cell receptor complex
  publication-title: Blood
  doi: 10.1182/blood.V91.2.585
– volume: 176
  start-page: 327
  year: 1992
  ident: 2025030706084892100_r42
  article-title: Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.176.2.327
– volume: 10
  start-page: 31
  year: 2013
  ident: 2025030706084892100_r5
  article-title: Molecular signatures of T-cell inhibition in HIV-1 infection
  publication-title: Retrovirology
  doi: 10.1186/1742-4690-10-31
– volume: 8
  start-page: 1246
  year: 2007
  ident: 2025030706084892100_r15
  article-title: Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1515
– volume: 72
  start-page: 917
  year: 2012
  ident: 2025030706084892100_r23
  article-title: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-1620
– volume: 104
  start-page: 8029
  year: 2007
  ident: 2025030706084892100_r28
  article-title: Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0702257104
– volume: 98
  start-page: 11644
  year: 2001
  ident: 2025030706084892100_r46
  article-title: Naive CD4 T cells inhibit CD28-costimulated R5 HIV replication in memory CD4 T cells
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.211205098
– volume: 172
  start-page: 5450
  year: 2004
  ident: 2025030706084892100_r29
  article-title: Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.172.9.5450
– volume: 168
  start-page: 3874
  year: 2002
  ident: 2025030706084892100_r38
  article-title: Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.168.8.3874
– volume: 187
  start-page: 3493
  year: 2011
  ident: 2025030706084892100_r22
  article-title: Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1100714
– volume: 182
  start-page: 5891
  year: 2009
  ident: 2025030706084892100_r8
  article-title: PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0803771
– volume: 30
  start-page: 535
  year: 2014
  ident: 2025030706084892100_r34
  article-title: Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8 T cells that is associated with lower viral load
  publication-title: AIDS Res. Hum. Retroviruses
  doi: 10.1089/aid.2012.0195
– volume: 205
  start-page: 2763
  year: 2008
  ident: 2025030706084892100_r13
  article-title: Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20081398
SSID ssj0006024
Score 2.4941852
Snippet T cells develop functional defects during HIV-1 infection, partially due to the upregulation of inhibitory receptors such as programmed death-1 (PD-1) and...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 3873
SubjectTerms Adult
Animals
Antigens, CD - immunology
CD4-Positive T-Lymphocytes - immunology
CD4-Positive T-Lymphocytes - pathology
CD8-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - pathology
Disease Progression
Female
Gene Expression Regulation - immunology
Histocompatibility Antigens Class II - immunology
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - pathology
Human immunodeficiency virus
Human immunodeficiency virus 1
Humans
Macaca mulatta
Male
Middle Aged
Programmed Cell Death 1 Receptor - immunology
Title The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/25780040
https://www.proquest.com/docview/1671214436
https://www.proquest.com/docview/1808710185
Volume 194
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEGgvCAZs5SYjwQOqwnKxc3msYKODbryk0LcodhyIVKXV2kjAL9nP5ZzYuWyUafASRZYbt_m--lx9DiGvXDtKZeBzi0uwdEBi-FboMW6lqZ2zNOJCuXh2-PTMn8zYxzmfDwYXvaylaiPeyl9bz5X8D6owBrjiKdl_QLZ9KAzAPeALV0AYrjfGuFqd63byRvObjj9YHoYA4hE65dejTOWY2j5KR-tKrNp-XdoDi2LNeAPVj-9YA6hJT5bYtmOBmqieaSI5OqFLF_NAX8nk5IulE7pAc4UF0K2z7mu83dkzXZ4Cz6Pouk-v6-ia3fNFxIV2x86LFHsJffvDqz0uF0Xrqi0qky-w7KICetpXVfS9GQ7HwIw-z9lswBzMWd825bG3jDW7tu6NbOgZ9vZgL9TNUa4KBwbGEAoH80NBRqA9tqUO99nn5Hg2nSbx0Ty-RW67YIBgb4z3J59aGe_bul1y8810ABxXOLz6_MsKz1-smFqbie-TewYQOtacekAGqtwjd3Rj0p975O6pSbl4SC4AQNonGV3mtCYZhfuY1iSjhmQ0pZdIRpE6tCMZ7UhGgWS0I5meaUhGeySjRUn7JKMNyR6R2fFR_G5imXYelvQ8d2NFIpSS5V6UKZmluc0CGXDmy1DxjLFMBkAHJ-U-E1EQSgHSJY9g23A9IbCMoPIek51yWaoDQpWQ0slFDmoXY4AFkFV4PItA_ZQq53JIDpt3nkhT6x5briwSsHkRpaRBKTEoDcmb9hMrXeflmrkvGxgT2IzxPaelWlbrxPEDB2sQetfNCe0wwDp5fEj2NQfaFVF-olh9coMVnpLd7g_0jOxsziv1HBTkjXhRc_U3_6PB7w
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+upregulation+of+LAG-3+on+T+cells+defines+a+subpopulation+with+functional+exhaustion+and+correlates+with+disease+progression+in+HIV-infected+subjects&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Tian%2C+Xiaoling&rft.au=Zhang%2C+Anli&rft.au=Qiu%2C+Chao&rft.au=Wang%2C+Wei&rft.date=2015-04-15&rft.issn=1550-6606&rft.eissn=1550-6606&rft.volume=194&rft.issue=8&rft.spage=3873&rft_id=info:doi/10.4049%2Fjimmunol.1402176&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon